The stock has a 36-month beta value of 0.61. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CODX is 31.11M, and at present, short sellers hold a 0.45% of that float. On May 22, 2025, the average trading volume of CODX was 282.74K shares.
CODX) stock’s latest price update
The stock of Co-Diagnostics Inc (NASDAQ: CODX) has increased by 4.98 when compared to last closing price of 0.25. Despite this, the company has experienced a -12.29% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-14 that Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.
CODX’s Market Performance
CODX’s stock has fallen by -12.29% in the past week, with a monthly drop of -24.34% and a quarterly drop of -62.03%. The volatility ratio for the week is 21.16% while the volatility levels for the last 30 days are 14.58% for Co-Diagnostics Inc The simple moving average for the past 20 days is -19.44% for CODX’s stock, with a -68.37% simple moving average for the past 200 days.
Analysts’ Opinion of CODX
Many brokerage firms have already submitted their reports for CODX stocks, with Sidoti repeating the rating for CODX by listing it as a “Neutral.” The predicted price for CODX in the upcoming period, according to Sidoti is $5 based on the research report published on August 12, 2022 of the previous year 2022.
Sidoti, on the other hand, stated in their research note that they expect to see CODX reach a price target of $14. The rating they have provided for CODX stocks is “Buy” according to the report published on December 29th, 2021.
CODX Trading at -26.09% from the 50-Day Moving Average
After a stumble in the market that brought CODX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.99% of loss for the given period.
Volatility was left at 14.58%, however, over the last 30 days, the volatility rate increased by 21.16%, as shares sank -29.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.46% lower at present.
During the last 5 trading sessions, CODX fell by -17.20%, which changed the moving average for the period of 200-days by -75.93% in comparison to the 20-day moving average, which settled at $0.3316. In addition, Co-Diagnostics Inc saw -64.31% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CODX
Current profitability levels for the company are sitting at:
- -40.79 for the present operating margin
- -0.12 for the gross margin
The net margin for Co-Diagnostics Inc stands at -35.79. The total capital return value is set at -0.82. Equity return is now at value -56.80, with -50.57 for asset returns.
Based on Co-Diagnostics Inc (CODX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -15.23.
Currently, EBITDA for the company is -38.7 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 9.14. The receivables turnover for the company is 7.35for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.43.
Conclusion
To sum up, Co-Diagnostics Inc (CODX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
